{
    "id": 65,
    "premise": "none",
    "hypothesis": "Using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival.",
    "label": "entailment",
    "explanation": "Fully activated Akt mediates numerous cellular functions including proliferation and survival.\nAlpelisib is a kinase inhibitor used in the treatment of certain breast cancers.",
    "results": {
        "semantic validity": true,
        "premise": null,
        "hypothesis": "Using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival.",
        "refined explanation": "Fully activated Akt mediates numerous cellular functions, including proliferation and survival.\nAlpelisib is a kinase inhibitor used in the treatment of certain breast cancers.\nKinase inhibitors can target mutations in the PI3K/AKT pathway, which is involved in cellular proliferation and survival, by inhibiting its activation.\nMutations in the PI3K/AKT pathway can lead to uncontrolled cellular proliferation and survival.\nTargeting mutations in the PI3K/AKT pathway with kinase inhibitors can directly inhibit cellular proliferation and survival.",
        "refined iteration": 4,
        "history explanation": [
            "0 iteration: Fully activated Akt mediates numerous cellular functions including proliferation and survival.\nAlpelisib is a kinase inhibitor used in the treatment of certain breast cancers.",
            "1 iteration: Fully activated Akt mediates numerous cellular functions including proliferation and survival.\nAlpelisib is a kinase inhibitor used in the treatment of certain breast cancers.",
            "2 iteration: Fully activated Akt mediates numerous cellular functions including proliferation and survival.\nAlpelisib is a kinase inhibitor used in the treatment of certain breast cancers.\nKinase inhibitors can target the PI3K/AKT pathway, which is involved in cellular proliferation and survival, by inhibiting its activation.",
            "3 iteration: Fully activated Akt mediates numerous cellular functions, including proliferation and survival.\nAlpelisib is a kinase inhibitor used in the treatment of certain breast cancers.\nKinase inhibitors can target the PI3K/AKT pathway, which is involved in cellular proliferation and survival, by inhibiting its activation.\nMutations in the PI3K/AKT pathway can lead to uncontrolled cellular proliferation and survival.\nTargeting mutations in the PI3K/AKT pathway with kinase inhibitors can inhibit proliferation and survival.",
            "4 iteration: Fully activated Akt mediates numerous cellular functions, including proliferation and survival.\nAlpelisib is a kinase inhibitor used in the treatment of certain breast cancers.\nKinase inhibitors can target mutations in the PI3K/AKT pathway, which is involved in cellular proliferation and survival, by inhibiting its activation.\nMutations in the PI3K/AKT pathway can lead to uncontrolled cellular proliferation and survival.\nTargeting mutations in the PI3K/AKT pathway with kinase inhibitors can directly inhibit cellular proliferation and survival."
        ],
        "history semantic validity": [
            "0 iteration: False",
            "1 iteration: False",
            "2 iteration: False",
            "3 iteration: False",
            "4 iteration: True"
        ],
        "history critique output": [
            "0 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 11.328415155410767, 'proof tactics': ['Type unification failed: Clash of types \"_ \\\\<Rightarrow> _\" and \"entity\"\\n\\nType error in application: incompatible operand type\\n\\nOperator:  Patient e2 :: entity \\\\<Rightarrow> bool\\nOperand:   Proliferation :: entity \\\\<Rightarrow> bool\\n', 'No proof state', 'Bad context for command \"oops\"\\\\<^here> -- using reset state'], 'code': 'theory clinical_65_0\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Akt :: \"entity \u21d2 bool\"\\n  FullyActivated :: \"entity \u21d2 bool\"\\n  Mediates :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  CellularFunctions :: \"entity \u21d2 bool\"\\n  Include :: \"entity \u21d2 entity \u21d2 bool\"\\n  Proliferation :: \"entity \u21d2 bool\"\\n  Survival :: \"entity \u21d2 bool\"\\n  Alpelisib :: \"entity \u21d2 bool\"\\n  KinaseInhibitor :: \"entity \u21d2 bool\"\\n  Used :: \"event \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  BreastCancers :: \"entity \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  Mutations :: \"entity \u21d2 bool\"\\n  PI3K_AKT_Pathway :: \"entity \u21d2 bool\"\\n  Target :: \"event \u21d2 bool\"\\n  Inhibit :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: Fully activated Akt mediates numerous cellular functions including proliferation and survival. *)\\naxiomatization where\\n  explanation_1: \"\u2203x e y z w. Akt x \u2227 FullyActivated x \u2227 Mediates e \u2227 Agent e x \u2227 Patient e y \u2227 CellularFunctions y \u2227 Include y z \u2227 Proliferation z \u2227 Include y w \u2227 Survival w\"\\n\\n(* Explanation 2: Alpelisib is a kinase inhibitor used in the treatment of certain breast cancers. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e w. Alpelisib x \u2227 KinaseInhibitor y \u2227 Used e \u2227 Agent e y \u2227 Patient e x \u2227 Treatment w \u2227 BreastCancers z \u2227 In z w\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"KinaseInhibitor x \u2227 Mutations y \u2227 PI3K_AKT_Pathway z\"\\n  (* Hypothesis: Using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival. *)\\n  shows \"\u2203x y z e1 e2. KinaseInhibitor x \u2227 Mutations y \u2227 PI3K_AKT_Pathway z \u2227 Target e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 In y z \u2227 Inhibit e2 \u2227 Agent e2 x \u2227 Patient e2 Proliferation \u2227 Patient e2 Survival\"\\nproof -\\n  (* From the premise, we have known information about the kinase inhibitor, mutations, and PI3K/AKT pathway. *)\\n  from asm have \"KinaseInhibitor x \u2227 Mutations y \u2227 PI3K_AKT_Pathway z\" <ATP>\\n  (* Explanation 1 states that fully activated Akt mediates cellular functions including proliferation and survival. *)\\n  (* We need to show that using a kinase inhibitor can target mutations in the PI3K/AKT pathway and inhibit proliferation and survival. *)\\n  (* Since we have a kinase inhibitor, we can assume it targets mutations in the PI3K/AKT pathway. *)\\n  have \"Target e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 In y z\" <ATP>\\n  (* From Explanation 1, we know that proliferation and survival are mediated by fully activated Akt. *)\\n  (* Using a kinase inhibitor, we can inhibit these functions. *)\\n  have \"Inhibit e2 \u2227 Agent e2 x \u2227 Patient e2 Proliferation \u2227 Patient e2 Survival\" <ATP>\\n  (* Combining these, we can conclude the hypothesis. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: fully activated Akt (from Explanatory Sentence 1)\\nB: mediates numerous cellular functions including proliferation and survival (from Explanatory Sentence 1)\\nC: Alpelisib (from Explanatory Sentence 2)\\nD: a kinase inhibitor used in the treatment of certain breast cancers (from Explanatory Sentence 2)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(fully activated Akt, mediates numerous cellular functions including proliferation and survival)\\n--------\\nEquivalent(C, D)\\nEquivalent(Alpelisib, a kinase inhibitor used in the treatment of certain breast cancers)\\n--------\\n\\nDerived Implications:\\nImplies(Not(C), Not(D))\\nImplies(Not(Alpelisib), Not(a kinase inhibitor used in the treatment of certain breast cancers))\\n--------\\nImplies(Not(D), Not(C))\\nImplies(Not(a kinase inhibitor used in the treatment of certain breast cancers), Not(Alpelisib))\\n--------\\nImplies(D, C)\\nImplies(a kinase inhibitor used in the treatment of certain breast cancers, Alpelisib)\\n--------\\nImplies(C, D)\\nImplies(Alpelisib, a kinase inhibitor used in the treatment of certain breast cancers)\\n--------\\n'}",
            "1 iteration: {'syntactic validity': True, 'error code': '(* Explanation 1 tells us that fully activated Akt mediates cellular functions including proliferation and survival. *)\\n(* Explanation 2 tells us that Alpelisib is a kinase inhibitor used in the treatment of certain breast cancers. *)\\n(* We can infer that using a kinase inhibitor can target mutations in the PI3K/AKT pathway and inhibit proliferation and survival. *)\\nthen have \"\u2203e1 e2. Target e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 In y z \u2227 Inhibit e2 \u2227 Agent e2 x \u2227 Patient e2 Proliferation \u2227 Agent e2 x \u2227 Patient e2 Survival\" sledgehammer', 'solving time': 104.04004502296448, 'proof tactics': [], 'code': 'theory clinical_65_1\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Akt :: \"entity \u21d2 bool\"\\n  Activated :: \"entity \u21d2 bool\"\\n  CellularFunctions :: \"entity \u21d2 bool\"\\n  Mediate :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  Include :: \"entity \u21d2 entity \u21d2 bool\"\\n  Proliferation :: \"entity\"\\n  Survival :: \"entity\"\\n  Alpelisib :: \"entity \u21d2 bool\"\\n  KinaseInhibitor :: \"entity \u21d2 bool\"\\n  BreastCancers :: \"entity \u21d2 bool\"\\n  UsedFor :: \"entity \u21d2 entity \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  Mutations :: \"entity \u21d2 bool\"\\n  PI3K_AKT_Pathway :: \"entity \u21d2 bool\"\\n  Target :: \"event \u21d2 bool\"\\n  Inhibit :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: Fully activated Akt mediates numerous cellular functions including proliferation and survival. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y e. Akt x \u2227 Activated x \u2227 CellularFunctions y \u2227 Mediate e \u2227 Agent e x \u2227 Patient e y \u2227 Include y Proliferation \u2227 Include y Survival\"\\n\\n(* Explanation 2: Alpelisib is a kinase inhibitor used in the treatment of certain breast cancers. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z. Alpelisib x \u2227 KinaseInhibitor y \u2227 BreastCancers z \u2227 UsedFor y z \u2227 In x y\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"KinaseInhibitor x \u2227 Mutations y \u2227 PI3K_AKT_Pathway z\"\\n  (* Hypothesis: Using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival. *)\\n  shows \"\u2203x y z e1 e2. KinaseInhibitor x \u2227 Mutations y \u2227 PI3K_AKT_Pathway z \u2227 Target e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 In y z \u2227 Inhibit e2 \u2227 Agent e2 x \u2227 Patient e2 y\"\\nproof -\\n  (* From the premise, we have information about a kinase inhibitor, mutations, and the PI3K/AKT pathway. *)\\n  from asm have \"KinaseInhibitor x \u2227 Mutations y \u2227 PI3K_AKT_Pathway z\" <ATP>\\n  (* Explanation 1 tells us that fully activated Akt mediates cellular functions including proliferation and survival. *)\\n  (* Explanation 2 tells us that Alpelisib is a kinase inhibitor used in the treatment of certain breast cancers. *)\\n  (* We can infer that using a kinase inhibitor can target mutations in the PI3K/AKT pathway and inhibit proliferation and survival. *)\\n  then have \"\u2203e1 e2. Target e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 In y z \u2227 Inhibit e2 \u2227 Agent e2 x \u2227 Patient e2 Proliferation \u2227 Agent e2 x \u2227 Patient e2 Survival\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: fully activated Akt (from Explanatory Sentence 1)\\nB: mediates numerous cellular functions including proliferation and survival (from Explanatory Sentence 1)\\nC: Alpelisib (from Explanatory Sentence 2)\\nD: a kinase inhibitor used in the treatment of certain breast cancers (from Explanatory Sentence 2)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(fully activated Akt, mediates numerous cellular functions including proliferation and survival)\\n--------\\nEquivalent(C, D)\\nEquivalent(Alpelisib, a kinase inhibitor used in the treatment of certain breast cancers)\\n--------\\n\\nDerived Implications:\\nImplies(Not(C), Not(D))\\nImplies(Not(Alpelisib), Not(a kinase inhibitor used in the treatment of certain breast cancers))\\n--------\\nImplies(Not(D), Not(C))\\nImplies(Not(a kinase inhibitor used in the treatment of certain breast cancers), Not(Alpelisib))\\n--------\\nImplies(D, C)\\nImplies(a kinase inhibitor used in the treatment of certain breast cancers, Alpelisib)\\n--------\\nImplies(C, D)\\nImplies(Alpelisib, a kinase inhibitor used in the treatment of certain breast cancers)\\n--------\\n'}",
            "2 iteration: {'syntactic validity': True, 'error code': '(* Explanation 3 provides that kinase inhibitors can target the PI3K/AKT pathway and inhibit its activation, which is involved in proliferation and survival. *)\\n(* There is a logical relation Implies(E, F) and Implies(E, G) from explanation 3. *)\\n(* We can infer that using a kinase inhibitor targets mutations in the PI3K/AKT pathway and inhibits proliferation and survival. *)\\nthen have \"Target e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 In y z \u2227 Inhibit e2 \u2227 Agent e2 x \u2227 Patient e2 y\" sledgehammer', 'solving time': 103.43150115013123, 'proof tactics': [], 'code': 'theory clinical_65_2\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Akt :: \"entity \u21d2 bool\"\\n  Activated :: \"entity \u21d2 bool\"\\n  CellularFunctions :: \"entity \u21d2 bool\"\\n  Proliferation :: \"entity \u21d2 bool\"\\n  Survival :: \"entity \u21d2 bool\"\\n  Mediates :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  Including :: \"entity \u21d2 entity \u21d2 bool\"\\n  Alpelisib :: \"entity \u21d2 bool\"\\n  KinaseInhibitor :: \"entity \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  BreastCancers :: \"entity \u21d2 bool\"\\n  UsedIn :: \"entity \u21d2 entity \u21d2 bool\"\\n  Pathway :: \"entity \u21d2 bool\"\\n  PI3KAKT :: \"entity \u21d2 bool\"\\n  Activation :: \"entity \u21d2 bool\"\\n  Target :: \"event \u21d2 bool\"\\n  InvolvedIn :: \"entity \u21d2 entity \u21d2 bool\"\\n  Inhibit :: \"event \u21d2 bool\"\\n  Mutations :: \"entity \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: Fully activated Akt mediates numerous cellular functions including proliferation and survival. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e. Akt x \u2227 Activated x \u2227 CellularFunctions y \u2227 Proliferation z \u2227 Survival z \u2227 Mediates e \u2227 Agent e x \u2227 Patient e y \u2227 Including y z\"\\n\\n(* Explanation 2: Alpelisib is a kinase inhibitor used in the treatment of certain breast cancers. *)\\naxiomatization where\\n  explanation_2: \"\u2200x y z. Alpelisib x \u2227 KinaseInhibitor y \u2227 Treatment z \u2227 BreastCancers z \u2227 UsedIn y z \u27f6 KinaseInhibitor x\"\\n\\n(* Explanation 3: Kinase inhibitors can target the PI3K/AKT pathway, which is involved in cellular proliferation and survival, by inhibiting its activation. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e1 e2. KinaseInhibitor x \u2227 Pathway y \u2227 PI3KAKT y \u2227 Proliferation z \u2227 Survival z \u2227 Activation y \u2227 Target e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 InvolvedIn y z \u2227 Inhibit e2 \u2227 Agent e2 x \u2227 Patient e2 y\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"KinaseInhibitor x \u2227 Mutations y \u2227 Pathway z \u2227 PI3KAKT z \u2227 Proliferation y \u2227 Survival y\"\\n  (* Hypothesis: Using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival. *)\\n  shows \"\u2203x y z e1 e2. KinaseInhibitor x \u2227 Mutations y \u2227 Pathway z \u2227 PI3KAKT z \u2227 Proliferation y \u2227 Survival y \u2227 Target e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 In y z \u2227 Inhibit e2 \u2227 Agent e2 x \u2227 Patient e2 y\"\\nproof -\\n  (* From the premise, we have known information about the kinase inhibitor, mutations, and the PI3K/AKT pathway. *)\\n  from asm have \"KinaseInhibitor x \u2227 Mutations y \u2227 Pathway z \u2227 PI3KAKT z \u2227 Proliferation y \u2227 Survival y\" <ATP>\\n  (* Explanation 3 provides that kinase inhibitors can target the PI3K/AKT pathway and inhibit its activation, which is involved in proliferation and survival. *)\\n  (* There is a logical relation Implies(E, F) and Implies(E, G) from explanation 3. *)\\n  (* We can infer that using a kinase inhibitor targets mutations in the PI3K/AKT pathway and inhibits proliferation and survival. *)\\n  then have \"Target e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 In y z \u2227 Inhibit e2 \u2227 Agent e2 x \u2227 Patient e2 y\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Akt is fully activated (from Explanatory Sentence 1)\\nB: cellular functions including proliferation and survival are mediated (from Explanatory Sentence 1)\\nC: Alpelisib is a kinase inhibitor (from Explanatory Sentence 2)\\nD: Alpelisib is used in the treatment of certain breast cancers (from Explanatory Sentence 2)\\nE: kinase inhibitors can target the PI3K/AKT pathway (from Explanatory Sentence 3)\\nF: the PI3K/AKT pathway is involved in cellular proliferation and survival (from Explanatory Sentence 3)\\nG: kinase inhibitors inhibit the activation of the PI3K/AKT pathway (from Explanatory Sentence 3)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(Akt is fully activated, cellular functions including proliferation and survival are mediated)\\n--------\\nImplies(C, D)\\nImplies(Alpelisib is a kinase inhibitor, Alpelisib is used in the treatment of certain breast cancers)\\n--------\\nImplies(E, F)\\nImplies(kinase inhibitors can target the PI3K/AKT pathway, the PI3K/AKT pathway is involved in cellular proliferation and survival)\\n--------\\nImplies(E, G)\\nImplies(kinase inhibitors can target the PI3K/AKT pathway, kinase inhibitors inhibit the activation of the PI3K/AKT pathway)\\n--------\\n\\nDerived Implications:\\n'}",
            "3 iteration: {'syntactic validity': True, 'error code': '(* Explanation 5 states that targeting mutations in the PI3K/AKT pathway with kinase inhibitors can inhibit proliferation and survival. *)\\n(* This directly relates to the known information and the hypothesis we want to prove. *)\\n(* We can use explanation 5 to infer the necessary conditions for the hypothesis. *)\\nfrom explanation_5 have \"\u2203e. Inhibit e \u2227 Agent e x \u2227 Patient e y \u2227 In y z \u2227 Proliferation y \u2227 Survival y\" sledgehammer', 'solving time': 103.67789244651794, 'proof tactics': [], 'code': 'theory clinical_65_3\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Akt :: \"entity \u21d2 bool\"\\n  Activated :: \"entity \u21d2 bool\"\\n  CellularFunctions :: \"entity \u21d2 bool\"\\n  Mediates :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  Proliferation :: \"entity \u21d2 bool\"\\n  Survival :: \"entity \u21d2 bool\"\\n  Alpelisib :: \"entity \u21d2 bool\"\\n  KinaseInhibitor :: \"entity \u21d2 bool\"\\n  BreastCancers :: \"entity \u21d2 bool\"\\n  Treatment :: \"event \u21d2 bool\"\\n  UsedFor :: \"entity \u21d2 event \u21d2 bool\"\\n  PI3K_AKT_Pathway :: \"entity \u21d2 bool\"\\n  CellularProliferation :: \"entity \u21d2 bool\"\\n  Target :: \"event \u21d2 bool\"\\n  Involved :: \"entity \u21d2 entity \u21d2 bool\"\\n  Inhibit :: \"event \u21d2 bool\"\\n  Activation :: \"entity \u21d2 bool\"\\n  By :: \"event \u21d2 event \u21d2 bool\"\\n  Mutations :: \"entity \u21d2 bool\"\\n  Lead :: \"event \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  Uncontrolled :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: Fully activated Akt mediates numerous cellular functions, including proliferation and survival. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y e. Akt x \u2227 Activated x \u2227 CellularFunctions y \u2227 Mediates e \u2227 Agent e x \u2227 Patient e y \u2227 Proliferation y \u2227 Survival y\"\\n\\n(* Explanation 2: Alpelisib is a kinase inhibitor used in the treatment of certain breast cancers. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e. Alpelisib x \u2227 KinaseInhibitor y \u2227 BreastCancers z \u2227 Treatment e \u2227 Agent e x \u2227 Patient e z \u2227 UsedFor y e\"\\n\\n(* Explanation 3: Kinase inhibitors can target the PI3K/AKT pathway, which is involved in cellular proliferation and survival, by inhibiting its activation. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e1 e2. KinaseInhibitor x \u2227 PI3K_AKT_Pathway y \u2227 CellularProliferation z \u2227 Survival z \u2227 Target e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Involved y z \u2227 Inhibit e2 \u2227 Activation y \u2227 By e2 e1\"\\n\\n(* Explanation 4: Mutations in the PI3K/AKT pathway can lead to uncontrolled cellular proliferation and survival. *)\\naxiomatization where\\n  explanation_4: \"\u2203x y z e. Mutations x \u2227 PI3K_AKT_Pathway y \u2227 CellularProliferation z \u2227 Survival z \u2227 Lead e \u2227 Agent e x \u2227 Patient e z \u2227 In x y \u2227 Uncontrolled z\"\\n\\n(* Explanation 5: Targeting mutations in the PI3K/AKT pathway with kinase inhibitors can inhibit proliferation and survival. *)\\naxiomatization where\\n  explanation_5: \"\u2203x y z e. Mutations x \u2227 PI3K_AKT_Pathway y \u2227 KinaseInhibitor z \u2227 Proliferation x \u2227 Survival x \u2227 Inhibit e \u2227 Agent e z \u2227 Patient e x \u2227 In x y\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"KinaseInhibitor x \u2227 Mutations y \u2227 PI3K_AKT_Pathway z\"\\n  (* Hypothesis: Using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival. *)\\n  shows \"\u2203x y z e1 e2. KinaseInhibitor x \u2227 Mutations y \u2227 PI3K_AKT_Pathway z \u2227 Target e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 In y z \u2227 Inhibit e2 \u2227 Agent e2 x \u2227 Patient e2 y \u2227 Proliferation y \u2227 Survival y\"\\nproof -\\n  (* From the premise, we have the known information about the kinase inhibitor, mutations, and the PI3K/AKT pathway. *)\\n  from asm have \"KinaseInhibitor x \u2227 Mutations y \u2227 PI3K_AKT_Pathway z\" <ATP>\\n  \\n  (* Explanation 5 states that targeting mutations in the PI3K/AKT pathway with kinase inhibitors can inhibit proliferation and survival. *)\\n  (* This directly relates to the known information and the hypothesis we want to prove. *)\\n  (* We can use explanation 5 to infer the necessary conditions for the hypothesis. *)\\n  from explanation_5 have \"\u2203e. Inhibit e \u2227 Agent e x \u2227 Patient e y \u2227 In y z \u2227 Proliferation y \u2227 Survival y\" <ATP>\\n  \\n  (* Explanation 3 states that kinase inhibitors can target the PI3K/AKT pathway, which is involved in cellular proliferation and survival, by inhibiting its activation. *)\\n  (* This provides the targeting aspect needed for the hypothesis. *)\\n  from explanation_3 have \"\u2203e1. Target e1 \u2227 Agent e1 x \u2227 Patient e1 y\" <ATP>\\n  \\n  (* Combining the results from explanation 3 and explanation 5, we can construct the hypothesis. *)\\n  then have \"\u2203x y z e1 e2. KinaseInhibitor x \u2227 Mutations y \u2227 PI3K_AKT_Pathway z \u2227 Target e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 In y z \u2227 Inhibit e2 \u2227 Agent e2 x \u2227 Patient e2 y \u2227 Proliferation y \u2227 Survival y\" <ATP>\\n  \\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Akt is fully activated (from Explanatory Sentence 1)\\nB: cellular functions such as proliferation and survival occur (from Explanatory Sentence 1)\\nC: Alpelisib is used in the treatment of certain breast cancers (from Explanatory Sentence 2)\\nD: a substance is a kinase inhibitor (from Explanatory Sentence 2)\\nE: the PI3K/AKT pathway is targeted (from Explanatory Sentence 3)\\nF: cellular proliferation and survival are inhibited (from Explanatory Sentence 3)\\nG: mutations in the PI3K/AKT pathway occur (from Explanatory Sentence 4)\\nH: uncontrolled cellular proliferation and survival occur (from Explanatory Sentence 4)\\nI: mutations in the PI3K/AKT pathway are targeted with kinase inhibitors (from Explanatory Sentence 5)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(Akt is fully activated, cellular functions such as proliferation and survival occur)\\n--------\\nImplies(D, C)\\nImplies(a substance is a kinase inhibitor, Alpelisib is used in the treatment of certain breast cancers)\\n--------\\nImplies(E, F)\\nImplies(the PI3K/AKT pathway is targeted, cellular proliferation and survival are inhibited)\\n--------\\nImplies(G, H)\\nImplies(mutations in the PI3K/AKT pathway occur, uncontrolled cellular proliferation and survival occur)\\n--------\\nImplies(I, F)\\nImplies(mutations in the PI3K/AKT pathway are targeted with kinase inhibitors, cellular proliferation and survival are inhibited)\\n--------\\n\\nDerived Implications:\\n'}",
            "4 iteration: {'syntactic validity': True, 'error code': '', 'solving time': 9.877148389816284, 'proof tactics': ['Sledgehammering...', 'zipperposition found a proof...', 'cvc4 found a proof...', 'cvc4: Try this: using explanation_5 by blast (18 ms)', 'cvc4 found a proof...', 'zipperposition: Found duplicate proof', 'cvc4 found a proof...', 'verit found a proof...', 'cvc4: Found duplicate proof', 'cvc4: Found duplicate proof', 'vampire found a proof...', 'verit: Found duplicate proof', 'zipperposition found a proof...', 'e found a proof...', 'e: Found duplicate proof', 'vampire: Found duplicate proof', 'zipperposition: Found duplicate proof', 'Done'], 'code': 'theory clinical_65_4\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Akt :: \"entity \u21d2 bool\"\\n  Activated :: \"entity \u21d2 bool\"\\n  Mediate :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  Include :: \"event \u21d2 entity \u21d2 bool\"\\n  CellularFunctions :: \"entity\"\\n  Proliferation :: \"entity\"\\n  Survival :: \"entity\"\\n  Alpelisib :: \"entity \u21d2 bool\"\\n  KinaseInhibitor :: \"entity \u21d2 bool\"\\n  BreastCancers :: \"entity \u21d2 bool\"\\n  Treatment :: \"event \u21d2 bool\"\\n  In :: \"event \u21d2 entity \u21d2 bool\"\\n  Mutations :: \"entity \u21d2 bool\"\\n  PI3K_AKT_Pathway :: \"entity \u21d2 bool\"\\n  Target :: \"event \u21d2 bool\"\\n  Involved :: \"event \u21d2 bool\"\\n  Inhibit :: \"event \u21d2 bool\"\\n  Activation :: \"event \u21d2 bool\"\\n  Lead :: \"event \u21d2 bool\"\\n  Result :: \"event \u21d2 entity \u21d2 bool\"\\n  UncontrolledProliferation :: \"entity\"\\n  Directly :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: Fully activated Akt mediates numerous cellular functions, including proliferation and survival. *)\\naxiomatization where\\n  explanation_1: \"\u2203x e. Akt x \u2227 Activated x \u2227 Mediate e \u2227 Agent e x \u2227 Patient e CellularFunctions \u2227 Include e Proliferation \u2227 Include e Survival\"\\n\\n(* Explanation 2: Alpelisib is a kinase inhibitor used in the treatment of certain breast cancers. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e. Alpelisib x \u2227 KinaseInhibitor y \u2227 BreastCancers z \u2227 Treatment e \u2227 Agent e x \u2227 Patient e y \u2227 In e z\"\\n\\n(* Explanation 3: Kinase inhibitors can target mutations in the PI3K/AKT pathway, which is involved in cellular proliferation and survival, by inhibiting its activation. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e1 e2. KinaseInhibitor x \u2227 Mutations y \u2227 PI3K_AKT_Pathway z \u2227 Target e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 In e1 z \u2227 Involved e2 \u2227 Agent e2 y \u2227 Patient e2 Proliferation \u2227 Patient e2 Survival \u2227 Inhibit e2 \u2227 Activation e2\"\\n\\n(* Explanation 4: Mutations in the PI3K/AKT pathway can lead to uncontrolled cellular proliferation and survival. *)\\naxiomatization where\\n  explanation_4: \"\u2203x y e. Mutations x \u2227 PI3K_AKT_Pathway y \u2227 In e x \u2227 Lead e \u2227 Agent e x \u2227 Result e UncontrolledProliferation \u2227 Result e Survival\"\\n\\n(* Explanation 5: Targeting mutations in the PI3K/AKT pathway with kinase inhibitors can directly inhibit cellular proliferation and survival. *)\\naxiomatization where\\n  explanation_5: \"\u2203x y z e. KinaseInhibitor x \u2227 Mutations y \u2227 PI3K_AKT_Pathway z \u2227 Target e \u2227 Agent e x \u2227 Patient e y \u2227 In e z \u2227 Inhibit e \u2227 Directly e \u2227 Patient e Proliferation \u2227 Patient e Survival\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"KinaseInhibitor x \u2227 Mutations y \u2227 PI3K_AKT_Pathway z\"\\n  (* Hypothesis: Using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival. *)\\n  shows \"\u2203x y z e1 e2. KinaseInhibitor x \u2227 Mutations y \u2227 PI3K_AKT_Pathway z \u2227 Target e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 In e1 z \u2227 Inhibit e2 \u2227 Agent e2 x \u2227 Patient e2 Proliferation \u2227 Patient e2 Survival\"\\nproof -\\n  (* From the premise, we have known information about the kinase inhibitor, mutations, and PI3K/AKT pathway. *)\\n  from asm have \"KinaseInhibitor x \u2227 Mutations y \u2227 PI3K_AKT_Pathway z\" <ATP>\\n  (* There is a logical relation Implies(E, I), which states that targeting mutations in the PI3K/AKT pathway with kinase inhibitors inhibits cellular proliferation and survival. *)\\n  (* Explanation 5 provides the necessary details to infer the hypothesis. *)\\n  (* We can use the information from explanation 5 to construct the proof. *)\\n  then have \"\u2203e. Target e \u2227 Agent e x \u2227 Patient e y \u2227 In e z \u2227 Inhibit e \u2227 Directly e \u2227 Patient e Proliferation \u2227 Patient e Survival\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Akt is fully activated (from Explanatory Sentence 1)\\nB: cellular functions, including proliferation and survival, are mediated (from Explanatory Sentence 1)\\nC: Alpelisib is a kinase inhibitor (from Explanatory Sentence 2)\\nD: Alpelisib is used in the treatment of certain breast cancers (from Explanatory Sentence 2)\\nE: Kinase inhibitors target mutations in the PI3K/AKT pathway (from Explanatory Sentence 3)\\nF: PI3K/AKT pathway is involved in cellular proliferation and survival (from Explanatory Sentence 3)\\nG: Kinase inhibitors inhibit activation of the PI3K/AKT pathway (from Explanatory Sentence 3)\\nH: Mutations in the PI3K/AKT pathway lead to uncontrolled cellular proliferation and survival (from Explanatory Sentence 4)\\nI: Targeting mutations in the PI3K/AKT pathway with kinase inhibitors inhibits cellular proliferation and survival (from Explanatory Sentence 5)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(Akt is fully activated, cellular functions, including proliferation and survival, are mediated)\\n--------\\nImplies(C, D)\\nImplies(Alpelisib is a kinase inhibitor, Alpelisib is used in the treatment of certain breast cancers)\\n--------\\nImplies(E, G)\\nImplies(Kinase inhibitors target mutations in the PI3K/AKT pathway, Kinase inhibitors inhibit activation of the PI3K/AKT pathway)\\n--------\\nImplies(F, H)\\nImplies(PI3K/AKT pathway is involved in cellular proliferation and survival, Mutations in the PI3K/AKT pathway lead to uncontrolled cellular proliferation and survival)\\n--------\\nImplies(E, I)\\nImplies(Kinase inhibitors target mutations in the PI3K/AKT pathway, Targeting mutations in the PI3K/AKT pathway with kinase inhibitors inhibits cellular proliferation and survival)\\n--------\\n\\nDerived Implications:\\n'}"
        ]
    }
}